Cell Based Assays – Immuno-Oncology
Coupling efficiency and diversity
The intricate interplay between the immune system and cancer dictates the efficacy of immuno-oncology therapies. For seasoned researchers navigating this dynamic landscape, robust and reliable cell-based assays are indispensable. Our carefully-curated portfolio delivers unparalleled insights into your candidate’s immunomodulatory potential, empowering you to unleash the full power of the immune system against cancer.
PharmaLegacy’s assays go beyond standard readouts, offering flexibility and depth tailored to your specific needs:
- Diverse target cell lines
- Effector cell populations
- High-throughput capabilities
- Multiplex cytokine and chemokine profiling
MODELS / SERVICES
Committed to quality:
- FDA part 11 compliant
- Animal studies strictly follow AAALAC and ILAC guidelines
- Electronically managed, traceable research data
- Rigorous adherence to international GLP and QA best practices
- Clients have real-time remote monitoring of studies
Want your scientific discoveries to become treatments? PharmaLegacy’s the right partner for you.
Providing Better Data For Critical Oncology Pipeline Decisions
To advance a compound from discovery to clinical, or to halt its development, is a huge and costly decision. For the benefit of you and your company, and for the well-being of patients in need of treatment, that decision needs to be based on correct information.
Download our Integrated In Vitro Oncology Assays brochure and see why over 300 pharmaceutical companies, including many global leaders, trust PharmaLegacy for the unbiased, accurate information they need to make critical oncology pipeline decisions.
We’re ready when you are.
Tell us your pharmacology challenges.
